News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,669 Results
Type
Article (41930)
Company Profile (267)
Press Release (673460)
Multimedia
Podcasts (73)
Webinars (16)
Section
Business (205890)
Career Advice (2027)
Deals (35643)
Drug Delivery (103)
Drug Development (81750)
Employer Resources (172)
FDA (16462)
Job Trends (14992)
News (348343)
Policy (33138)
Tag
Academia (2603)
Accelerated approval (15)
Adcomms (23)
Allergies (109)
Alliances (50285)
ALS (125)
Alzheimer's disease (1527)
Antibody-drug conjugate (ADC) (170)
Approvals (16488)
Artificial intelligence (360)
Autoimmune disease (39)
Automation (23)
Bankruptcy (363)
Best Places to Work (11683)
BIOSECURE Act (21)
Biosimilars (138)
Biotechnology (186)
Bladder cancer (112)
Brain cancer (39)
Breast cancer (410)
Cancer (3295)
Cardiovascular disease (265)
Career advice (1699)
Career pathing (32)
CAR-T (203)
CDC (35)
Cell therapy (553)
Cervical cancer (27)
Clinical research (67768)
Collaboration (1176)
Company closure (4)
Compensation (827)
Complete response letters (39)
COVID-19 (2699)
CRISPR (68)
C-suite (461)
Cystic fibrosis (120)
Data (3616)
Decentralized trials (2)
Denatured (25)
Depression (78)
Diabetes (380)
Diagnostics (6519)
Digital health (28)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (164)
Drug pricing (140)
Drug shortages (28)
Duchenne muscular dystrophy (171)
Earnings (88718)
Editorial (46)
Employer branding (21)
Employer resources (148)
Events (115349)
Executive appointments (893)
FDA (18580)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1043)
Gene editing (148)
Generative AI (26)
Gene therapy (436)
GLP-1 (837)
Government (4678)
Grass and pollen (5)
Guidances (330)
Healthcare (18934)
HIV (42)
Huntington's disease (32)
IgA nephropathy (47)
Immunology and inflammation (188)
Immuno-oncology (13)
Indications (45)
Infectious disease (2893)
Inflammatory bowel disease (165)
Inflation Reduction Act (10)
Influenza (78)
Intellectual property (152)
Interviews (314)
IPO (16670)
IRA (49)
Job creations (3680)
Job search strategy (1435)
Kidney cancer (13)
Labor market (63)
Layoffs (527)
Leadership (21)
Legal (7996)
Liver cancer (84)
Longevity (11)
Lung cancer (479)
Lymphoma (241)
Machine learning (21)
Management (58)
Manufacturing (501)
MASH (107)
Medical device (13622)
Medtech (13638)
Mergers & acquisitions (19774)
Metabolic disorders (934)
Multiple sclerosis (109)
NASH (16)
Neurodegenerative disease (156)
Neuropsychiatric disorders (36)
Neuroscience (2327)
NextGen: Class of 2025 (6566)
Non-profit (4521)
Now hiring (53)
Obesity (459)
Opinion (235)
Ovarian cancer (110)
Pain (135)
Pancreatic cancer (142)
Parkinson's disease (198)
Partnered (25)
Patents (362)
Patient recruitment (250)
Peanut (54)
People (58385)
Pharmaceutical (65)
Pharmacy benefit managers (21)
Phase I (21117)
Phase II (29825)
Phase III (22225)
Pipeline (2363)
Policy (238)
Postmarket research (2580)
Preclinical (9010)
Press Release (71)
Prostate cancer (159)
Psychedelics (40)
Radiopharmaceuticals (255)
Rare diseases (531)
Real estate (6016)
Recruiting (66)
Regulatory (23446)
Reports (51)
Research institute (2372)
Resumes & cover letters (351)
Rett syndrome (12)
RNA editing (12)
RSV (56)
Schizophrenia (106)
Series A (168)
Series B (130)
Service/supplier (11)
Sickle cell disease (70)
Special edition (19)
Spinal muscular atrophy (150)
Sponsored (35)
Startups (3649)
State (2)
Stomach cancer (14)
Supply chain (84)
Tariffs (73)
The Weekly (46)
Vaccines (887)
Venture capital (59)
Weight loss (282)
Women's health (51)
Worklife (17)
Date
Today (15)
Last 7 days (478)
Last 30 days (2053)
Last 365 days (31132)
2025 (21498)
2024 (35479)
2023 (40333)
2022 (51488)
2021 (56034)
2020 (54399)
2019 (46849)
2018 (35303)
2017 (32484)
2016 (31855)
2015 (37923)
2014 (31692)
2013 (26709)
2012 (28881)
2011 (29574)
2010 (27569)
Location
Africa (738)
Alabama (69)
Alaska (7)
Arizona (256)
Arkansas (13)
Asia (39140)
Australia (6354)
California (8521)
Canada (2626)
China (771)
Colorado (356)
Connecticut (362)
Delaware (223)
Europe (84344)
Florida (1267)
Georgia (285)
Hawaii (2)
Idaho (60)
Illinois (678)
India (39)
Indiana (401)
Iowa (18)
Japan (256)
Kansas (114)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1150)
Massachusetts (6258)
Michigan (264)
Minnesota (514)
Mississippi (4)
Missouri (102)
Montana (28)
Nebraska (25)
Nevada (97)
New Hampshire (68)
New Jersey (2331)
New Mexico (28)
New York (2317)
North Carolina (1184)
North Dakota (10)
Northern California (3848)
Ohio (262)
Oklahoma (17)
Oregon (36)
Pennsylvania (1798)
Puerto Rico (17)
Rhode Island (41)
South America (1114)
South Carolina (43)
South Dakota (1)
Southern California (3274)
Tennessee (138)
Texas (1305)
United States (31069)
Utah (254)
Virginia (210)
Washington D.C. (75)
Washington State (701)
West Virginia (4)
Wisconsin (71)
715,669 Results for "aziyo biologics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices
Aziyo Biologics, Inc. announced a change of the Company’s name to Elutia Inc.
September 6, 2023
·
5 min read
BioCapital
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs.
August 30, 2023
·
6 min read
Business
LeMaitre to Distribute Aziyo Biologics’ Cardiovascular Patches
LeMaitre Vascular, Inc., a provider of vascular devices, implants and services, announced it has entered into an agreement with Aziyo Biologics, Inc. to become the exclusive distributor of Aziyo’s cardiovascular patches in the United States.
April 20, 2023
·
1 min read
Business
Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo’s Cardiovascular Portfolio
Aziyo Biologics, Inc., a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, announced it has entered into a distribution agreement with LeMaitre Vascular, Inc., a provider of vascular devices, implants and services.
April 20, 2023
·
5 min read
Press Releases
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
August 29, 2025
·
9 min read
Business
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023.
July 31, 2023
·
1 min read
BioCapital
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products
Aziyo Biologics, Inc. announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures.
July 13, 2023
·
5 min read
Business
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
Aziyo Biologics, Inc. provided a business update and reported financial results for the second quarter ended June 30, 2023.
August 14, 2023
·
11 min read
Business
Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction
Aziyo Biologics, Inc. and Sientra, Inc. today announced they have entered into an agreement to expand the distribution of Aziyo’s SimpliDerm product line.
March 22, 2023
·
8 min read
BioCapital
Aziyo Biologics Presents Positive Clinical Data on CanGaroo® Biologic Envelope
Aziyo Biologics, Inc. today announced that positive data from the HEAL Study will be presented at Heart Rhythm Society (HRS 2023) on May 21, 2023, at 12:30 PM CT at the Morial Convention Center in New Orleans, LA.
May 19, 2023
·
5 min read
1 of 71,567
Next
